BioSpace News Archive

Digital therapeutics is tasked with the delivery of therapeutic interventions that are based on evidence. These deliveries is made to patients and are driven by advanced software programs so as to treat, manage, and avert a wide range of behavioral, metal, and physical conditions of a patient.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced its participation at upcoming investor conferences in October 2021.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per a comprehensive study by Fact.MR, the global assisted reproductive technology market is projected to grow at a healthy CAGR of 6.3% between 2020 and 2025.

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141, an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase enzyme for the treatment of Hunter syndrome.

Tirzepatide led to greater improvements in liver fat content and abdominal adipose tissue compared to titrated insulin degludec in adults with type 2 diabetes in an MRI sub-study of Eli Lilly and Company’s phase 3 SURPASS-3 clinical trial.1 The results were presented at the 57th European Association for the Study of Diabetes Annual Meeting in an EASD-sponsored symposium.

Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.

AIM ImmunoTech Inc. announced that AIM and hVIVO have a signed Clinical Trial Agreement for a Phase 2a Human Challenge Trial to test the company’s drug Ampligen as a potential intranasal prophylactic using a human rhinovirus and influenza A virus.

Electromedical Technologies, Inc . is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.

Pfizer Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved CIBINQO®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT